A systematic review of metformin to limit weight-gain with atypical antipsychotics
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Y. J. | - |
dc.contributor.author | Jeong, J. H. | - |
dc.date.available | 2019-05-29T11:33:33Z | - |
dc.date.issued | 2011-10 | - |
dc.identifier.issn | 0269-4727 | - |
dc.identifier.issn | 1365-2710 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/21195 | - |
dc.description.abstract | What is known and Objective: Weight-gain is commonly reported in patients taking atypical antipsychotic agents. A systematic review was performed to evaluate the effectiveness of metformin for attenuation of weight-gain induced by atypical antipsychotic agents. Methods: A PubMed database (1966-May 2010) search was conducted, using metformin, atypical antipsychotic and weight-gain as search terms. Review articles, letters and commentaries were excluded. Results and Discussion: Thirteen trials were identified (eight randomized, double-blind, placebo-controlled trials, one crossover adult trial, one open-label uncontrolled adult trial, two open-label uncontrolled paediatric trials and one case report). Of the eight randomized, double-blind, placebo-controlled trials, three studied adult subjects and one studied children. Metformin was well tolerated. The heterogeneity of the trials did not justify meta-analytic pooling of outcomes, and we provide a best evidence synthesis. What is new and Conclusion: There is limited evidence for the efficacy of metformin in limiting weight-gain induced by atypical antipsychotic agents. However, the evidence is weak and further well-powered randomized, double-blind, placebo-controlled studies of longer duration should be conducted to confirm the preliminary evidence and provide better estimates of effect. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.title | A systematic review of metformin to limit weight-gain with atypical antipsychotics | - |
dc.type | Article | - |
dc.identifier.doi | 10.1111/j.1365-2710.2011.01255.x | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, v.36, no.5, pp 537 - 545 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000295049800001 | - |
dc.identifier.scopusid | 2-s2.0-80052838160 | - |
dc.citation.endPage | 545 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 537 | - |
dc.citation.title | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | - |
dc.citation.volume | 36 | - |
dc.type.docType | Review | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | atypical antipsychotic | - |
dc.subject.keywordAuthor | metformin | - |
dc.subject.keywordAuthor | weight-gain | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | LIFE-STYLE INTERVENTION | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | 1ST-EPISODE SCHIZOPHRENIA | - |
dc.subject.keywordPlus | METABOLIC DYSFUNCTION | - |
dc.subject.keywordPlus | OLANZAPINE TREATMENT | - |
dc.subject.keywordPlus | PEDIATRIC-PATIENTS | - |
dc.subject.keywordPlus | OBESITY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | INSULIN | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.